Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 288

1.

Evidence for the involvement of dopamine transporters in behavioral stimulant effects of modafinil.

Zolkowska D, Jain R, Rothman RB, Partilla JS, Roth BL, Setola V, Prisinzano TE, Baumann MH.

J Pharmacol Exp Ther. 2009 May;329(2):738-46. doi: 10.1124/jpet.108.146142. Epub 2009 Feb 5.

2.

Preclinical evaluation of GBR12909 decanoate as a long-acting medication for methamphetamine dependence.

Baumann MH, Phillips JM, Ayestas MA, Ali SF, Rice KC, Rothman RB.

Ann N Y Acad Sci. 2002 Jun;965:92-108.

PMID:
12105088
3.

Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal.

Broderick PA, Hope O, Okonji C, Rahni DN, Zhou Y.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):157-71.

PMID:
14687870
5.

Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo.

Tolliver BK, Newman AH, Katz JL, Ho LB, Fox LM, Hsu K Jr, Berger SP.

J Pharmacol Exp Ther. 1999 Apr;289(1):110-22.

6.

Persistent antagonism of methamphetamine-induced dopamine release in rats pretreated with GBR12909 decanoate.

Baumann MH, Ayestas MA, Sharpe LG, Lewis DB, Rice KC, Rothman RB.

J Pharmacol Exp Ther. 2002 Jun;301(3):1190-7.

7.
8.

Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro.

Madras BK, Xie Z, Lin Z, Jassen A, Panas H, Lynch L, Johnson R, Livni E, Spencer TJ, Bonab AA, Miller GM, Fischman AJ.

J Pharmacol Exp Ther. 2006 Nov;319(2):561-9. Epub 2006 Aug 2.

10.

Attenuation by the 5-HT1A receptor agonist osemozotan of the behavioral effects of single and repeated methamphetamine in mice.

Ago Y, Nakamura S, Uda M, Kajii Y, Abe M, Baba A, Matsuda T.

Neuropharmacology. 2006 Sep;51(4):914-22. Epub 2006 Jul 24.

PMID:
16863654
11.

[3H]substrate- and cell-specific effects of uptake inhibitors on human dopamine and serotonin transporter-mediated efflux.

Johnson RA, Eshleman AJ, Meyers T, Neve KA, Janowsky A.

Synapse. 1998 Sep;30(1):97-106.

PMID:
9704886
12.

Non-amphetaminic mechanism of stimulant locomotor effect of modafinil in mice.

Simon P, Hémet C, Ramassamy C, Costentin J.

Eur Neuropsychopharmacol. 1995 Dec;5(4):509-14.

PMID:
8998404
13.

The role of organic cation transporter-3 in methamphetamine disposition and its behavioral response in rats.

Nakayama H, Kitaichi K, Ito Y, Hashimoto K, Takagi K, Yokoi T, Takagi K, Ozaki N, Yamamoto T, Hasegawa T.

Brain Res. 2007 Dec 12;1184:260-9. Epub 2007 Oct 6.

PMID:
17988657
14.

Methamphetamine-induced rapid and reversible changes in dopamine transporter function: an in vitro model.

Sandoval V, Riddle EL, Ugarte YV, Hanson GR, Fleckenstein AE.

J Neurosci. 2001 Feb 15;21(4):1413-9.

15.

Appetite suppressants as agonist substitution therapies for stimulant dependence.

Rothman RB, Blough BE, Baumann MH.

Ann N Y Acad Sci. 2002 Jun;965:109-26.

PMID:
12105089
16.
17.

Escalating dose pretreatment induces pharmacodynamic and not pharmacokinetic tolerance to a subsequent high-dose methamphetamine binge.

O'Neil ML, Kuczenski R, Segal DS, Cho AK, Lacan G, Melega WP.

Synapse. 2006 Nov;60(6):465-73.

PMID:
16897726
18.

GBR12909 attenuates cocaine-induced activation of mesolimbic dopamine neurons in the rat.

Baumann MH, Char GU, De Costa BR, Rice KC, Rothman RB.

J Pharmacol Exp Ther. 1994 Dec;271(3):1216-22.

PMID:
7996429
19.

Involvement of central histaminergic systems in modafinil-induced but not methylphenidate-induced increases in locomotor activity in rats.

Ishizuka T, Murakami M, Yamatodani A.

Eur J Pharmacol. 2008 Jan 14;578(2-3):209-15. Epub 2007 Sep 26.

PMID:
17920581
20.

Dopaminergic role in stimulant-induced wakefulness.

Wisor JP, Nishino S, Sora I, Uhl GH, Mignot E, Edgar DM.

J Neurosci. 2001 Mar 1;21(5):1787-94.

Supplemental Content

Support Center